These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
391 related articles for article (PubMed ID: 36077466)
21. Nanotheranostics for Diagnosis and Treatment of Breast Cancer. Patel P; Kumar K; Jain VK; Popli H; Yadav AK; Jain K Curr Pharm Des; 2023; 29(10):732-747. PubMed ID: 36999427 [TBL] [Abstract][Full Text] [Related]
22. Anti-EGF Receptor Aptamer-Guided Co-Delivery of Anti-Cancer siRNAs and Quantum Dots for Theranostics of Triple-Negative Breast Cancer. Kim MW; Jeong HY; Kang SJ; Jeong IH; Choi MJ; You YM; Im CS; Song IH; Lee TS; Lee JS; Lee A; Park YS Theranostics; 2019; 9(3):837-852. PubMed ID: 30809312 [TBL] [Abstract][Full Text] [Related]
23. Anti-CD44 and EGFR Dual-Targeted Solid Lipid Nanoparticles for Delivery of Doxorubicin to Triple-Negative Breast Cancer Cell Line: Preparation, Statistical Optimization, and Darabi F; Saidijam M; Nouri F; Mahjub R; Soleimani M Biomed Res Int; 2022; 2022():6253978. PubMed ID: 35845934 [TBL] [Abstract][Full Text] [Related]
24. Gold Nanoparticles in Triple-Negative Breast Cancer Therapeutics. Akter Z; Khan FZ; Khan MA Curr Med Chem; 2023; 30(3):316-334. PubMed ID: 34477507 [TBL] [Abstract][Full Text] [Related]
25. Therapeutic genome editing of triple-negative breast tumors using a noncationic and deformable nanolipogel. Guo P; Yang J; Huang J; Auguste DT; Moses MA Proc Natl Acad Sci U S A; 2019 Sep; 116(37):18295-18303. PubMed ID: 31451668 [TBL] [Abstract][Full Text] [Related]
26. Enhancing Targeted Therapy in Breast Cancer by Ultrasound-Responsive Nanocarriers. Edwards IA; De Carlo F; Sitta J; Varner W; Howard CM; Claudio PP Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982548 [TBL] [Abstract][Full Text] [Related]
27. Lipid polymer hybrid nanoparticles: a custom-tailored next-generation approach for cancer therapeutics. Gajbhiye KR; Salve R; Narwade M; Sheikh A; Kesharwani P; Gajbhiye V Mol Cancer; 2023 Oct; 22(1):160. PubMed ID: 37784179 [TBL] [Abstract][Full Text] [Related]
28. Special Issue: Nanotherapeutics in Women's Health Emerging Nanotechnologies for Triple-Negative Breast Cancer Treatment. Torres Quintas S; Canha-Borges A; Oliveira MJ; Sarmento B; Castro F Small; 2024 Oct; 20(41):e2300666. PubMed ID: 36978237 [TBL] [Abstract][Full Text] [Related]
29. siRNA Functionalized Lipid Nanoparticles (LNPs) in Management of Diseases. Kalita T; Dezfouli SA; Pandey LM; Uludag H Pharmaceutics; 2022 Nov; 14(11):. PubMed ID: 36432711 [TBL] [Abstract][Full Text] [Related]
30. Blood-brain barrier-penetrating amphiphilic polymer nanoparticles deliver docetaxel for the treatment of brain metastases of triple negative breast cancer. He C; Cai P; Li J; Zhang T; Lin L; Abbasi AZ; Henderson JT; Rauth AM; Wu XY J Control Release; 2017 Jan; 246():98-109. PubMed ID: 28017889 [TBL] [Abstract][Full Text] [Related]
31. The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer. Wan X; Zheng X; Pang X; Zhang Z; Jing T; Xu W; Zhang Q Int J Pharm; 2015 Apr; 484(1-2):16-28. PubMed ID: 25700543 [TBL] [Abstract][Full Text] [Related]
32. Synthesis of micellar-like terpolymer nanoparticles with reductively-cleavable cross-links and evaluation of efficacy in 2D and 3D models of triple negative breast cancer. Monteiro PF; Gulfam M; Monteiro CJ; Travanut A; Abelha TF; Pearce AK; Jerôme C; Grabowska AM; Clarke PA; Collins HM; Heery DM; Gershkovich P; Alexander C J Control Release; 2020 Jul; 323():549-564. PubMed ID: 32371266 [TBL] [Abstract][Full Text] [Related]
33. Solid Matrix Based Lipidic Nanoparticles in Oral Cancer Chemotherapy: Applications and Pharmacokinetics. Ahmad J; Amin S; Rahman M; Rub RA; Singhal M; Ahmad MZ; Rahman Z; Addo RT; Ahmad FJ; Mushtaq G; Kamal MA; Akhter S Curr Drug Metab; 2015; 16(8):633-44. PubMed ID: 26264206 [TBL] [Abstract][Full Text] [Related]
35. Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice. Zhang T; Prasad P; Cai P; He C; Shan D; Rauth AM; Wu XY Acta Pharmacol Sin; 2017 Jun; 38(6):835-847. PubMed ID: 28216624 [TBL] [Abstract][Full Text] [Related]
36. DR5 antibody conjugated lipid-based nanocarriers of gamma-secretase inhibitor for the treatment of triple negative breast cancer. Pindiprolu SKSS; Krishnamurthy PT; Dev C; Chintamaneni PK Chem Phys Lipids; 2021 Mar; 235():105033. PubMed ID: 33385372 [TBL] [Abstract][Full Text] [Related]
37. Lipid Nanoparticles as a Promising Drug Delivery Carrier for Topical Ocular Therapy-An Overview on Recent Advances. Jacob S; Nair AB; Shah J; Gupta S; Boddu SHS; Sreeharsha N; Joseph A; Shinu P; Morsy MA Pharmaceutics; 2022 Feb; 14(3):. PubMed ID: 35335909 [TBL] [Abstract][Full Text] [Related]
38. In vivo β-catenin attenuation by the integrin α5-targeting nano-delivery strategy suppresses triple negative breast cancer stemness and metastasis. Li Y; Xiao Y; Lin HP; Reichel D; Bae Y; Lee EY; Jiang Y; Huang X; Yang C; Wang Z Biomaterials; 2019 Jan; 188():160-172. PubMed ID: 30352320 [TBL] [Abstract][Full Text] [Related]
39. The use of nanomaterials as drug delivery systems and anticancer agents in the treatment of triple-negative breast cancer: an updated review (year 2005 to date). Ndongwe T; Zhou AA; Ganga NP; Matawo N; Sibanda U; Chidziwa TV; Witika BA; Krause RWM; Matlou GG; Siwe-Noundou X Discov Nano; 2024 Sep; 19(1):138. PubMed ID: 39225730 [TBL] [Abstract][Full Text] [Related]
40. Nanotechnology revolutionises breast cancer treatment: harnessing lipid-based nanocarriers to combat cancer cells. Fatima Qizilbash F; Sartaj A; Qamar Z; Kumar S; Imran M; Mohammed Y; Ali J; Baboota S; Ali A J Drug Target; 2023 Sep; 31(8):794-816. PubMed ID: 37525966 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]